Interpace Biosciences®, Inc. Quarterly report pursuant to Section 13 or 15(d)

Quarterly report pursuant to Section 13 or 15(d)

Note 11 - Discontinued Operations (Tables)

Note 11 - Discontinued Operations (Tables)

9 Months Ended

Sep. 30, 2016

Notes Tables

Schedule of Components of Loss from Discontinued Operations [Table Text Block]

		Three Months Ending September 30,								Nine Months Ending September 30,
		2016				2015				2016				2015
Revenue, net		$	-			$	34,119			$	1,644			$	104,408

(Loss) income from discontinued operations			(414	)			2,576				(1,006	)			6,615
Gain on sale of assets			-				-				1,326				217
(Loss) income from discontinued operations, before tax			(414	)			2,576				320				6,832
Income tax (benefit) expense			(117	)			2				219				4
(Loss) income from discontinued operations, net of tax		$	(297	)		$	2,574			$	101			$	6,828

Discontinued Operation, Schedule of Amounts Recognized in Balance Sheet [Table Text Block]

		For the Nine Months Ended September 30, 2016												For the Year Ended December 31, 2015
		CSO				DCA/TVG				Total				CSO				DCA/TVG				Total
Accounts receivable, net		$	-			$	-			$	-			$	3,296			$	-			$	3,296
Unbilled receivable, net			-				-				-				16				-				16
Other			-				150				150				2,062				-				2,062
Current assets from discontinued operations			-				150				150				5,374				-				5,374
Property and equipment, net			-				-				-				190				-				190
Other			-				-				-				-				150				150
Long-term assets from discontinued operations			-				-				-				190				150				340
Total assets		$	-			$	150			$	150			$	5,564			$	150			$	5,714

Accounts payable		$	947			$	-			$	947			$	3,767			$	-			$	3,767
Unearned contract revenue			-				-				-				11				-				11
Accrued salary and bonus			1,686				-				1,686				3,036				-				3,036
Other			2,052				70				2,122				5,092				358				5,450
Current liabilities from discontinued operations			4,685				70				4,755				11,906				358				12,264
Total liabilities		$	4,685			$	70			$	4,755			$	11,906			$	358			$	12,264